BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 36113897)

  • 1. HSP90α induces immunosuppressive myeloid cells in melanoma via TLR4 signaling.
    Arkhypov I; Özbay Kurt FG; Bitsch R; Novak D; Petrova V; Lasser S; Hielscher T; Groth C; Lepper A; Hu X; Li W; Utikal J; Altevogt P; Umansky V
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36113897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Melanoma Extracellular Vesicles Generate Immunosuppressive Myeloid Cells by Upregulating PD-L1 via TLR4 Signaling.
    Fleming V; Hu X; Weller C; Weber R; Groth C; Riester Z; Hüser L; Sun Q; Nagibin V; Kirschning C; Bronte V; Utikal J; Altevogt P; Umansky V
    Cancer Res; 2019 Sep; 79(18):4715-4728. PubMed ID: 31337655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the
    Chevolet I; Speeckaert R; Schreuer M; Neyns B; Krysko O; Bachert C; Hennart B; Allorge D; van Geel N; Van Gele M; Brochez L
    Oncoimmunology; 2015 Mar; 4(3):e982382. PubMed ID: 25949897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
    Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
    J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells.
    Azzaoui I; Uhel F; Rossille D; Pangault C; Dulong J; Le Priol J; Lamy T; Houot R; Le Gouill S; Cartron G; Godmer P; Bouabdallah K; Milpied N; Damaj G; Tarte K; Fest T; Roussel M
    Blood; 2016 Aug; 128(8):1081-92. PubMed ID: 27338100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of Inhibitory Molecules (Arginase-1, IDO, and PD-L1) by Myeloid-Derived Suppressor Cells in Multiple Myeloma Patients in Remission.
    Tyrinova TV; Batorov EV; Aristova TA; Ushakova GY; Sizikova SA; Denisova VV; Ostanin AA; Chernykh ER
    Bull Exp Biol Med; 2022 Nov; 174(1):71-75. PubMed ID: 36437327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunosuppressive capacity of circulating MDSC predicts response to immune checkpoint inhibitors in melanoma patients.
    Petrova V; Groth C; Bitsch R; Arkhypov I; Simon SCS; Hetjens S; Müller V; Utikal J; Umansky V
    Front Immunol; 2023; 14():1065767. PubMed ID: 36860876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of extracellular vesicles and PD-L1 in glioblastoma-mediated immunosuppressive monocyte induction.
    Himes BT; Peterson TE; de Mooij T; Garcia LMC; Jung MY; Uhm S; Yan D; Tyson J; Jin-Lee HJ; Parney D; Abukhadra Y; Gustafson MP; Dietz AB; Johnson AJ; Dong H; Maus RL; Markovic S; Lucien F; Parney IF
    Neuro Oncol; 2020 Jul; 22(7):967-978. PubMed ID: 32080744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secreted heat shock protein 90alpha induces colorectal cancer cell invasion through CD91/LRP-1 and NF-kappaB-mediated integrin alphaV expression.
    Chen JS; Hsu YM; Chen CC; Chen LL; Lee CC; Huang TS
    J Biol Chem; 2010 Aug; 285(33):25458-66. PubMed ID: 20558745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-induced peripheral immunosuppression promotes brain metastasis in patients with non-small cell lung cancer.
    Li YD; Lamano JB; Lamano JB; Quaggin-Smith J; Veliceasa D; Kaur G; Biyashev D; Unruh D; Bloch O
    Cancer Immunol Immunother; 2019 Sep; 68(9):1501-1513. PubMed ID: 31489465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secreted heat shock protein 90α (HSP90α) induces nuclear factor-κB-mediated TCF12 protein expression to down-regulate E-cadherin and to enhance colorectal cancer cell migration and invasion.
    Chen WS; Chen CC; Chen LL; Lee CC; Huang TS
    J Biol Chem; 2013 Mar; 288(13):9001-10. PubMed ID: 23386606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy.
    Vanderstraeten A; Luyten C; Verbist G; Tuyaerts S; Amant F
    Cancer Immunol Immunother; 2014 Jun; 63(6):545-57. PubMed ID: 24658839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Immune Checkpoint Blockade on Myeloid-Derived Suppressor Cell Populations in Patients With Melanoma.
    Sun SH; Benner B; Savardekar H; Lapurga G; Good L; Abood D; Nagle E; Duggan M; Stiff A; DiVincenzo MJ; Suarez-Kelly LP; Campbell A; Yu L; Wesolowski R; Howard H; Shah H; Kendra K; Carson WE
    Front Immunol; 2021; 12():740890. PubMed ID: 34712230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immune function of myeloid-derived suppressor cells and its mechanism in obstructive sleep apnea syndrome].
    Chen SW; Li J; Xiang B; Xu SJ; Wang L
    Zhonghua Yi Xue Za Zhi; 2020 Feb; 100(4):295-300. PubMed ID: 32075359
    [No Abstract]   [Full Text] [Related]  

  • 15. Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma.
    Johnson DB; Bordeaux J; Kim JY; Vaupel C; Rimm DL; Ho TH; Joseph RW; Daud AI; Conry RM; Gaughan EM; Hernandez-Aya LF; Dimou A; Funchain P; Smithy J; Witte JS; McKee SB; Ko J; Wrangle JM; Dabbas B; Tangri S; Lameh J; Hall J; Markowitz J; Balko JM; Dakappagari N
    Clin Cancer Res; 2018 Nov; 24(21):5250-5260. PubMed ID: 30021908
    [No Abstract]   [Full Text] [Related]  

  • 16. Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma.
    Serratì S; Guida M; Di Fonte R; De Summa S; Strippoli S; Iacobazzi RM; Quarta A; De Risi I; Guida G; Paradiso A; Porcelli L; Azzariti A
    Mol Cancer; 2022 Jan; 21(1):20. PubMed ID: 35042524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gut-derived lipopolysaccharide remodels tumoral microenvironment and synergizes with PD-L1 checkpoint blockade via TLR4/MyD88/AKT/NF-κB pathway in pancreatic cancer.
    Yin H; Pu N; Chen Q; Zhang J; Zhao G; Xu X; Wang D; Kuang T; Jin D; Lou W; Wu W
    Cell Death Dis; 2021 Oct; 12(11):1033. PubMed ID: 34718325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accumulation of blood-circulating PD-L1-expressing M-MDSCs and monocytes/macrophages in pretreatment ovarian cancer patients is associated with soluble PD-L1.
    Okła K; Rajtak A; Czerwonka A; Bobiński M; Wawruszak A; Tarkowski R; Bednarek W; Szumiło J; Kotarski J
    J Transl Med; 2020 Jun; 18(1):220. PubMed ID: 32487171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade.
    Grauers Wiktorin H; Nilsson MS; Kiffin R; Sander FE; Lenox B; Rydström A; Hellstrand K; Martner A
    Cancer Immunol Immunother; 2019 Feb; 68(2):163-174. PubMed ID: 30315349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
    Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
    Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.